Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT von O'Brien, Neil A, McDonald, Karen, Tong, Luo, von Euw, Erika, Kalous, Ondrej, Conklin, Dylan, Hurvitz, Sara A, di Tomaso, Emmanuelle, Schnell, Christian, Linnartz, Ronald, Finn, Richard S, Hirawat, Samit, Slamon, Dennis J

Volltext

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL von Eustace, Alex J, Conlon, Neil T, McDermott, Martina S J, Browne, Brigid C, O'Leary, Patrick, Holmes, Frankie A, Espina, Virginia, Liotta, Lance A, O'Shaughnessy, Joyce, Gallagher, Clair, O'Driscoll, Lorraine, Rani, Sweta, Madden, Stephen F, O'Brien, Neil A, Ginther, Charles, Slamon, Dennis, Walsh, Naomi, Gallagher, William M, Zagozdzon, Radoslaw, Watson, William R, O'Donovan, Norma, Crown, John

Volltext

Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib von Kalous, Ondrej, Conklin, Dylan, Desai, Amrita J, O'Brien, Neil A, Ginther, Charles, Anderson, Lee, Cohen, David J, Britten, Carolyn D, Taylor, Ian, Christensen, James G, Slamon, Dennis J, Finn, Richard S

Volltext

Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells von Konecny, Gottfried E, Kolarova, Teodora, O'Brien, Neil A, Winterhoff, Boris, Yang, Guorong, Qi, Jingwei, Qi, Zhengdong, Venkatesan, Natarajan, Ayala, Raul, Luo, Tong, Finn, Richard S, Kristof, Jessica, Galderisi, Chad, Porta, Diana Graus, Anderson, Lee, Shi, Michael M, Yovine, Alejandro, Slamon, Dennis J

Volltext

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer von O'Brien, Neil A, McDermott, Martina S J, Conklin, Dylan, Luo, Tong, Ayala, Raul, Salgar, Suruchi, Chau, Kevin, DiTomaso, Emmanuelle, Babbar, Naveen, Su, Faye, Gaither, Alex, Hurvitz, Sara A, Linnartz, Ronald, Rose, Kristine, Hirawat, Samit, Slamon, Dennis J

Volltext

Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib von O'Brien, Neil A, Browne, Brigid C, Chow, Lucy, Wang, Yuhua, Ginther, Charles, Arboleda, Jane, Duffy, Michael J, Crown, John, O'Donovan, Norma, Slamon, Dennis J

Volltext

Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors von McDermott, Martina S J, O'Brien, Neil A, Hoffstrom, Benjamin, Gong, KeWei, Lu, Ming, Zhang, Jun, Luo, Tong, Liang, Min, Jia, Weiping, Hong, Jenny J, Chau, Kevin, Davenport, Simon, Xie, Bin, Press, Michael F, Panayiotou, Richard, Handly-Santana, Abram, Brugge, Joan S, Presta, Leonard, Glaspy, John, Slamon, Dennis J

Volltext

Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers von O'Brien, Neil A, McDermott, Martina S J, Zhang, Jun, Gong, Ke Wei, Lu, Ming, Hoffstrom, Benjamin, Luo, Tong, Ayala, Raul, Chau, Kevin, Liang, Min, Madrid, Athena M, Donahue, Timothy R, Glaspy, John A, Presta, Leonard, Slamon, Dennis J

Volltext

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer von Canonici, Alexandra, Ivers, Laura, Conlon, Neil T., Pedersen, Kasper, Gaynor, Nicola, Browne, Brigid C., O’Brien, Neil A., Gullo, Giuseppe, Collins, Denis M., O’Donovan, Norma, Crown, John

Volltext

Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies von O'Brien, Neil A, Huang, Holly K T, McDermott, Martina S J, Madrid, Athena M, Luo, Tong, Ayala, Raul, Issakhanian, Shawnt, Gong, Ke Wei, Lu, Ming, Zhang, Jun, Slamon, Dennis J

Volltext

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells von McDermott, Martina S J, Conlon, Neil, Browne, Brigid C, Szabo, Adam, Synnott, Naoise C, O'Brien, Neil A, Duffy, Michael J, Crown, John, O'Donovan, Norma

Volltext

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells von Canonici, Alexandra, Qadir, Zulfiqar, Conlon, Neil T., Collins, Denis M., O’Brien, Neil A., Walsh, Naomi, Eustace, Alex J., O’Donovan, Norma, Crown, John

Volltext

In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response von Hurvitz, Sara A., Kalous, Ondrej, Conklin, Dylan, Desai, Amrita J., Dering, Judy, Anderson, Lee, O’Brien, Neil A., Kolarova, Teodora, Finn, Richard S., Linnartz, Ronald, Chen, David, Slamon, Dennis J.

Volltext

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy von McDermott, Martina Sj, Browne, Brigid C, Conlon, Neil T, O'Brien, Neil A, Slamon, Dennis J, Henry, Michael, Meleady, Paula, Clynes, Martin, Dowling, Paul, Crown, John, O'Donovan, Norma

Volltext

Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy von McDermott, Martina S. J., Browne, Brigid C., Conlon, Neil T., O’Brien, Neil A., Slamon, Dennis J., Henry, Michael, Meleady, Paula, Clynes, Martin, Dowling, Paul, Crown, John, O’Donovan, Norma

Volltext

EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells von Dillard, Christen, Kiyohara, Meagan, Mah, Vei, McDermott, Sean P, Bazzoun, Dana, Tsui, Jessica, Chan, Ann M, Haddad, Ghassan, Pellegrini, Matteo, Chang, Yu-Ling, Elshimali, Yahya, Wu, Yanyuan, Vadgama, Jaydutt V, Kim, Sara R, Goodglick, Lee, Law, Samuel M, Patel, Deven D, Dhawan, Puneet, O'Brien, Neil A, Gordon, Lynn K, Braun, Jonathan, Lazar, Gary, Wicha, Max S, Wadehra, Madhuri

Volltext

Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer von Wainberg, Zev A, Anghel, Adrian, Rogers, Amy M, Desai, Amrita J, Kalous, Ondrej, Conklin, Dylan, Ayala, Raul, O'Brien, Neil A, Quadt, Cornelia, Akimov, Mikhail, Slamon, Dennis J, Finn, Richard S

Volltext

Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells von Mcdermott, Martina S.J., Canonici, Alexandra, Ivers, Laura, Browne, Brigid C., Madden, Stephen F., O'brien, Neil A., Crown, John, O'Donovan, Norma

Volltext

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer von Canonici, Alexandra, Gijsen, Merel, Mullooly, Maeve, Bennett, Ruth, Bouguern, Noujoude, Pedersen, Kasper, O'Brien, Neil A, Roxanis, Ioannis, Li, Ji-Liang, Bridge, Esther, Finn, Richard, Siamon, Dennis, McGowan, Patricia, Duffy, Michael J, O'Donovan, Norma, Crown, John, Kong, Anthony

Volltext

Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses von Diwanji, Rohan, O'Brien, Neil A, Choi, Jiyoung E, Nguyen, Beverly, Laszewski, Tyler, Grauel, Angelo L, Yan, Zheng, Xu, Xin, Wu, Jincheng, Ruddy, David A, Piquet, Michelle, Pelletier, Marc R, Savchenko, Alexander, Charette, LaSalette, Rodrik-Outmezguine, Vanessa, Baum, Jason, Millholland, John M, Wong, Connie C, Martin, Anne-Marie, Dranoff, Glenn, Pruteanu-Malinici, Iulian, Cremasco, Viviana, Sabatos-Peyton, Catherine, Jayaraman, Pushpa

Volltext